Revolutionizing Peptide Drugs with Radical Enzymes | Dr. Karsten Eastman, Ph.D.
Originally on
Progress, Potential, and Possibilities · hosted by Ira Pastor
The guest
Dr. Karsten Eastman, PhD
CEO & Co-Founder, Sethera Therapeutics
CEO and co-founder of Sethera Therapeutics, whose PhD discovery of a promiscuous radical SAM enzyme opened new chemical space for peptide drug manufacturing. Published in PNAS.
In this episode
- Radical SAM enzymology for peptide drug manufacturing
- The PapB enzyme: stapling peptides into polymacrocyclic architectures
- Targeting currently undruggable diseases with novel peptide chemistry
- Building a platform company at the intersection of enzymology and drug discovery
Listen & watch
Keep listening